Additionally, they showed that CD8+ tumor infiltrating lymphocytes treated with CD3:CD19 bi-specific antibodies were able to kill breast cancer cells as efficiently as peripheral blood mononuclear cells from the same patients (52). Here, CD8A is linked to neoplasm.